EP Patent

EP0389282A2 — Xanthinederivatives, process for their preparation and their pharmaceutical use

Assigned to Beecham Group PLC · Expires 1990-09-26 · 36y expired

What this patent protects

A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): or if appropriate a pharmaceuticall…

USPTO Abstract

A method for the treatment of cerebrovascular disorders and/or disorders associated with cerebral senility and/or other disorders which method comprises the administration of an effective, non-toxic amount of a compound of formula (I): or if appropriate a pharmaceutically acceptable salt thereof, wherein R¹ and R² each independently represent alkyl or a moiety of formula (a): -(CH₂) m -A      (a) wherein m represents zero or an integer 1, 2 or 3; A represents a substituted or unsubstituted cyclic hydrocarbon radical; and R³ represents a halogen atom, a nitro group, or a group -NR⁴R⁵ wherein R⁴ and R⁵ each independently represents hydrogen, alkyl or alkylcarbonyl or R⁴ and R⁵ together with the nitrogen to which they are attached forming an optionally substituted, heterocyclic group; certain novel compounds falling within formula (I) and compositions comprising such compounds.

Drugs covered by this patent

Patent Metadata

Patent number
EP0389282A2
Jurisdiction
EP
Classification
Expires
1990-09-26
Drug substance claim
No
Drug product claim
No
Assignee
Beecham Group PLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.